Xilio Therapeutics (XLO) EBITDA (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of EBITDA data on file, last reported at -$14.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 1.88% year-over-year to -$14.1 million; the trailing twelve-month figure through Mar 2026 stood at -$42.2 million (up 25.82% YoY), and the FY2025 full-year result was -$42.0 million, up 30.7% from the prior year.
• EBITDA eased to -$14.1 million in Q1 2026, from -$11.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.9 million in Q3 2025 to a low of -$24.6 million in Q2 2022.
• A 5-year average of -$16.8 million and a median of -$17.4 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA decreased 28.47% in 2022 and surged 86.93% in 2025, its largest moves.
• Tracing XLO's EBITDA over 5 years: stood at -$23.2 million in 2022, then climbed by 21.74% to -$18.1 million in 2023, then increased by 24.83% to -$13.6 million in 2024, then increased by 13.16% to -$11.8 million in 2025, then decreased by 19.23% to -$14.1 million in 2026.
• Business Quant data shows XLO's EBITDA at -$14.1 million in Q1 2026, -$11.8 million in Q4 2025, and -$1.9 million in Q3 2025.